WILLIAM LAGOR to CRISPR-Cas Systems
This is a "connection" page, showing publications WILLIAM LAGOR has written about CRISPR-Cas Systems.
Connection Strength
2.787
-
Treating Cardiovascular Disease with Liver Genome Engineering. Curr Atheroscler Rep. 2022 02; 24(2):75-84.
Score: 0.620
-
Anti-Cas9 immunity: A formidable challenge for muscle genome editing. Mol Ther. 2022 01 05; 30(1):10-12.
Score: 0.610
-
Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. Sci Rep. 2017 03 16; 7:44624.
Score: 0.439
-
In vivo editing of the pan-endothelium by immunity evading simian adenoviral vector. Biomed Pharmacother. 2023 Feb; 158:114189.
Score: 0.164
-
In Vivo Gene Editing in Lipid and Atherosclerosis Research. Methods Mol Biol. 2022; 2419:673-713.
Score: 0.153
-
AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway. Mol Ther. 2022 Jan 05; 30(1):238-243.
Score: 0.151
-
Depletion of essential isoprenoids and ER stress induction following acute liver-specific deletion of HMG-CoA reductase. J Lipid Res. 2020 Dec; 61(12):1675-1686.
Score: 0.141
-
Gene Delivery in Lipid Research and Therapies. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):62-69.
Score: 0.124
-
In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Res. 2018 Sep 28; 123(8):953-963.
Score: 0.122
-
Rapid Disruption of Genes Specifically in Livers of Mice Using Multiplex CRISPR/Cas9 Editing. Gastroenterology. 2018 12; 155(6):1967-1970.e6.
Score: 0.121
-
CRISPR/Cas9: at the cutting edge of hepatology. Gut. 2017 07; 66(7):1329-1340.
Score: 0.111
-
What Do We Really Think About Human Germline Genome Editing, and What Does It Mean for Medicine? Circ Cardiovasc Genet. 2017 10; 10(5).
Score: 0.029